Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.08B
EPS-0.5300
P/E Ratio-9.91
Earnings Date08/06/2026

svra

Stock Based Compensation

Last Annual Value

14.42M

3-Year CAGR

92%

5-Year CAGR

23%

10-Year CAGR

18%

Savara Inc.

Savara Inc. Competitors Analysis of Stock Based Compensation

SVRA · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
14.42M
51.1%34.6%52.7% 
37.11M
9.7%9.5%33.3%
88.00K
-83.4%-59.5%-36.5%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
7.12M
-0.7%12.4%6.6%
15.01M
99.2%N/AN/A
26.43M
11.5%27.5%N/A
28.01M
N/A57.5%N/A
27.87M
32.2%30.2%27.5%
PROK logo
ProKidney Corp.
NASDAQ:PROK
25.34M
-6.3%105.0%N/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.25